Buy4

ALUMIS INC.

ALMS

Total Value

$11.7M

Net $9.7M bought

Filing Date

Sep 9, 2026

6 transactions

Purchases

$10.7M

4 transactions

Sales

$1.0M

2 transactions

Trade Summary

On Sep 4, 2026 through Sep 8, 2026, AKKARAJU SRINIVAS, Insider, purchased $11.7M of ALUMIS INC. (ALMS) across 6 transactions. The filing covers Common Stock and reflects net buying of $9.7M. Reported prices ranged from $10.55 to $11.17. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

ALMS daily price with the insider's purchase marked at $10.87.

Bought near the 6-month low · the stock trades 8% lower today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: AKKARAJU SRINIVAS
Role: Insider
Location: SOUTH SAN FRANCISCO, CA

Filing Details

Filing Date: Sep 9, 2026
Transaction Date: Sep 4, 2026
Accession Number: 0001231919-26-001158
Form Type: 4
Net Trading Amount: $9.7M

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Sep 4, 2026	Common Stock	220,070	$11.17	Purchase	$2.5M
Sep 4, 2026	Common Stock	220,070	$11.17	Purchase	$2.5M
Sep 8, 2026	Common Stock	48,066	$10.55	Sale	$507.0K
Sep 8, 2026	Common Stock	48,065	$10.55	Sale	$507.0K
Sep 8, 2026	Common Stock	273,291	$10.63	Purchase	$2.9M
Sep 8, 2026	Common Stock	273,290	$10.63	Purchase	$2.9M

Want live alerts when AKKARAJU SRINIVAS trades again?

Download Insider Trades to track ALMS, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
(F2)Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
(F3)Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
(F4)The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs.
(F5)The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
(F6)The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AKKARAJU SRINIVAS

(Last)

(First)

(Middle)

C/O ALUMIS INC.

280 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ALUMIS INC. [ ALMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/04/2026		P		220,070	A	$11.173⁽¹⁾	4,711,801	I	By Samsara BioCapital, L.P.⁽²⁾
Common Stock	09/04/2026		P		220,070	A	$11.173⁽¹⁾	2,073,558	I	By Samsara Opportunity Fund, L.P.⁽³⁾
Common Stock	09/08/2026		S⁽⁴⁾		48,066	D	$10.5484⁽⁵⁾	4,663,735	I	By Samsara BioCapital, L.P.⁽²⁾
Common Stock	09/08/2026		S⁽⁴⁾		48,065	D	$10.5484⁽⁵⁾	2,025,493	I	By Samsara Opportunity Fund, L.P.⁽³⁾
Common Stock	09/08/2026		P⁽⁴⁾		273,291	A	$10.6271⁽⁶⁾	4,937,026	I	By Samsara BioCapital, L.P.⁽²⁾
Common Stock	09/08/2026		P⁽⁴⁾		273,290	A	$10.6271⁽⁶⁾	2,298,783	I	By Samsara Opportunity Fund, L.P.⁽³⁾
Common Stock								3,553	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

2. Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

3. Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

4. The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs.

5. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

	/s/ Srinivas Akkaraju	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001231919-26-001158.

ALUMIS INC.

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Want live alerts when AKKARAJU SRINIVAS trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4

Price at the Time of the Trade